Status:
UNKNOWN
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Lead Sponsor:
Changhai Hospital
Conditions:
Bladder Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethr...
Detailed Description
NMIBC at medium to high risk showcases a recurrence rate of 40.5% post-TURBT, thus necessitating frequent monitoring and bladder instillation. Among patients with medium to high-risk NMIBC, the prefer...
Eligibility Criteria
Inclusion
- Participants aged ≥ 18 years and signed informed consent form.
- Participants diagnosed with median to high risk NMIBC underwent TURBT and received BCG instillation therapy.
Exclusion
- Participants with urinary tract infection
- Antibiotic treatment within the last month
- Immuno- /chemo- therapy within the past 6 months
- Immunosuppressive therapy
- Indwelling urinary catheter
- Additional major diagnosis known to affect the gut or bladder microbiota (e. g. liver cirrhosis, systemic sclerosis, inflammatory bowel disease, inflammatory bowel syndrome, celiac disease, neuropathic bladder)
- Participants with urothelial carcinoma accompanied by other malignancy.
- Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06153849
Start Date
December 1 2023
End Date
May 1 2025
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433